c.315+17C>T
SpliceS3Likely benignCytoplasmic · predictedS3 — Minimal predicted splicing impact (SpliceAI ΔS 0.00)
Interactive 3D Structure
AlphaFold wild-type wolframin · the variant site near residue 105 (N-terminal cytoplasmic (intrinsically disordered)) is highlighted.
Variant Assessment
Therapeutic Implication · S3
Clinical Evidence
Observed at very low frequency in gnomAD.
ClinVar classifies this variant as Likely benign for Cataract 41 (autosomal dominant, OMIM 116400); Wolfram-like syndrome (autosomal dominant, OMIM 614296); Nonsyndromic hearing loss (DFNA6/14/38) (autosomal dominant, OMIM 600965); WFS1-related diabetes (autosomal dominant); Wolfram syndrome (classic) (autosomal recessive, OMIM 222300). These are two clinically distinct disease families: classic Wolfram syndrome requires two affected copies, while the dominant WFS1-related disorders do not. One label covers both, and it does not tell you which applies to a given person.
- Cataract 41autosomal dominant · OMIM 116400submitted as: Cataract 41
- Wolfram-like syndromeautosomal dominant · OMIM 614296submitted as: Wolfram-like syndrome
- Nonsyndromic hearing loss (DFNA6/14/38)autosomal dominant · OMIM 600965submitted as: Autosomal dominant nonsyndromic hearing loss 6
- WFS1-related diabetesautosomal dominantsubmitted as: Type 2 diabetes mellitus
- Wolfram syndrome (classic)autosomal recessive · OMIM 222300submitted as: Wolfram syndrome 1
- Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
- Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.
Review status: 2★ multiple submitters, no conflicts. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.
Highest in African / African American: AF 0.0068% (5 of 73,528 alleles), in line with the global figure.
No homozygotes reported in gnomAD v4. For a recessive allele this is expected and is not, on its own, evidence either way.
| Ancestry group | Allele freq. | AC / AN | Hom. | Carrier est. |
|---|---|---|---|---|
| African / African American | 0.0068% | 5 / 73,528 | 0 | ~1 in 7350 |
| Admixed American | 0.0059% | 3 / 51,044 | 0 | ~1 in 8510 |
| Remaining individuals | 0.0050% | 3 / 60,084 | 0 | ~1 in 10010 |
| European (non-Finnish) | 0.0047% | 54 / 1,147,298 | 0 | ~1 in 10620 |
| Finnish | 0.0033% | 2 / 59,794 | 0 | ~1 in 14950 |
| South Asian · under-sampled | 0.0012% | 1 / 84,252 | 0 | — |
Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.
Feed this card to Wolfram Intelligence
Download the c.315+17C>T card below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals matched to this S3 splice variant and its domain context.
Full Variant Card
c.315+17C_T — WFS1 Molecular Atlas Card
Variant type: Splice site Boundary: donor (5' splice site) · intronic offset +17 Nearest protein position: ~105 (N-terminal cytoplasmic (intrinsically disordered))
Schema category: S3 — Minimal predicted splicing impact (SpliceAI ΔS 0.00)
SpliceAI predicts little splicing disruption at this donor (5') site (max ΔS 0.00 < 0.2; acceptor-gain 0.00, acceptor-loss 0.00, donor-gain 0.00, donor-loss 0.00). The variant may be tolerated or act through a weak/again-tissue-specific mechanism; wet-lab RNA validation is the arbiter before any therapeutic call.
Splice prediction
- Affected site: donor (5' splice site), extended splice region
- SpliceAI delta scores (GRCh38 chr4:6287192 C>T):
- acceptor gain 0.00 · acceptor loss 0.00
- donor gain 0.00 · donor loss 0.00
- Predicted outcome: Minimal predicted splicing impact (SpliceAI ΔS 0.00)
Clinical evidence
Inheritance and scope
Likely benign — for Cataract 41 (autosomal dominant, OMIM 116400); Wolfram-like syndrome (autosomal dominant, OMIM 614296); Nonsyndromic hearing loss (DFNA6/14/38) (autosomal dominant, OMIM 600965); WFS1-related diabetes (autosomal dominant); Wolfram syndrome (classic) (autosomal recessive, OMIM 222300)
ClinVar classifies this variant as Likely benign for Cataract 41 (autosomal dominant, OMIM 116400); Wolfram-like syndrome (autosomal dominant, OMIM 614296); Nonsyndromic hearing loss (DFNA6/14/38) (autosomal dominant, OMIM 600965); WFS1-related diabetes (autosomal dominant); Wolfram syndrome (classic) (autosomal recessive, OMIM 222300). These are two clinically distinct disease families: classic Wolfram syndrome requires two affected copies, while the dominant WFS1-related disorders do not. One label covers both, and it does not tell you which applies to a given person.
Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient. Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.
- Classification: Likely benign
- Review status: criteria provided, multiple submitters, no conflicts
- Associated conditions: Cataract 41; Wolfram-like syndrome; Autosomal dominant nonsyndromic hearing loss 6; Type 2 diabetes mellitus; Wolfram syndrome 1
- cDNA change: c.315+17C>T
- ClinVar accession: VCV001647181
- Last evaluated: 2025/02/05 00:00
- Submissions: 1
Card generated by wolfram-atlas-batch (splice pipeline) on 2026-06-08T07:49:55.628025Z.
Schema: reference/card_schema_extension.md (S1–S3). WFS1: UniProt O76024, AlphaFold v6.